Determinants of costs and benefits in atopic dermatitis routine care in Germany.
Nicole ZanderMatthias AugustinL ZeerviT BieberT WerfelAndreas WollenbergAnna K LangenbruchPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
Gender, education and implemented prevention measures are significant cost determinants in AD. The results confirm that treatment with biologics is the main cost driver in AD. However, incremental patient-relevant benefits of high-priced therapy are reflected by the significantly better clinical outcomes in the group treated with biologics.